Search Results
Nov 19, 2025, 12:04 ET November Issue of Journal of Cardiac Failure-Intersections Highlights Advances in Right Ventricular Reserve, Revascularization Strategies, and LVAD Deactivation
forward understanding of heart failure mechanisms, clinical care, and multidisciplinary management. The issue spans topics from cost-effectiveness in CABG vs PCI in ischemic cardiomyopathy to insights from TOPCAT—and features a timely State-of-the-Art Review examining the evolving concept of right ventricular
More news about: Heart Failure Society of America
Nov 19, 2025, 10:01 ET Hepatitis B and C Therapeutics Market Surges to US$17.02 Billion in 2024 as Innovation, National Screening Policies, and Next-Gen Antivirals Transform Global Care | According to DataM Intelligence
Market Segmentation with 2024 Market Size and Shares By Indication: Hepatitis B (HBV) vs. Hepatitis C (HCV) In 2024, the market remained dominated by Hepatitis C therapeutics, supported by
More news about: DataM Intelligence 4 Market Research LLP
Nov 19, 2025, 09:32 ET Canopy Study Selected for Oral Presentation at ASH 2025
identified. Findings show a reduction in infection-related hospitalizations among patients using the Canopy RTM system (2.6% vs. 4.5%; RR 0.48; p=0.0147). Additional analyses across infection-related outcomes—including emergency department utilization and outpatient antibiotic
More news about: Canopy
Nov 19, 2025, 09:01 ET Violence in brick-and-mortar retail surges, threatening retention of staff ahead of the holiday shopping season, new research from the Loss Prevention Research Council and Verkada finds
experiencing workplace violence at notably higher rates than women, are also significantly more likely to quit over safety concerns in the next year (63% vs. 39% of women). Store managers are feeling the impact of this retention challenge: nearly half (49%) report that safety concerns are a barrier to hiring,
More news about: Verkada
Nov 19, 2025, 09:00 ET Builders Launches Interactive AI Tool 'Ima' to Give All Texans a Voice in Policymaking
About BuildersAt Builders, we believe the real divide isn't left vs. right; it's between those solving problems and those fueling division. We're a cross-partisan, non-profit initiative working to move beyond "us vs. them" thinking and solve problems together. We help people build the mindset,
More news about: Builders Movement
Nov 19, 2025, 09:00 ET Seedtag Releases First-of-Its-Kind Neuroscience Study Redefining Human-Centered Advertising Effectiveness
3.5x higher neural engagement vs. non-contextual ads +30% lift in neural engagement vs. standard contextual ads +26% increase in positive,
More news about: Seedtag
Nov 19, 2025, 08:54 ET Parks Associates releases S.O.S. State of Streaming Report at Future of Video
Elevation through Aggregation, Featured by Philo Value vs. Cost: For the Love of Ads, Featured by InterDigital Sports and Live Content as Growth Engines, Featured
More news about: Parks Associates
Nov 19, 2025, 08:46 ET Entrepreneurs Are Heading To The Heartland: Report Ranks South Dakota No. 1 For New Business
posted stronger Q2 2025 GDP growth (3.6% vs. 3.0%) and better five-year survival rates (51.6% vs. 50.5%). Lower Costs vs. Greater Capital: Red states benefit from cheaper energy (11.8¢/kWh vs. 18.6¢) and lighter taxes, while blue
More news about: National Business Capital
Nov 19, 2025, 08:00 ET Supermicro kondigt nieuwe AI-fabrieksclusteroplossingen aan op basis van NVIDIA Enterprise Reference Architectures en NVIDIA Blackwell AI-infrastructuur om de implementatie van AI op schaal te vereenvoudigen
volgende generatie, van cloud tot edge, aan te bieden aan onze wereldwijde klanten. Onze producten worden in eigen huis ontworpen en geproduceerd (in de VS, Taiwan en Nederland). Hierbij maken we gebruik van wereldwijde faciliteiten voor schaal en efficiëntie, geoptimaliseerd om de TCO te verlagen en de impact
More news about: Super Micro Computer, Inc.
Nov 19, 2025, 07:30 ET Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
with the primary endpoint assessment occurring at the end of the 18-week timepoint. In the first Phase 3 study, a treatment response of 49% (p<0.0001 vs patients receiving placebo in Cycle 1) was observed in patients completing 18 weeks (3 cycles) of therapy. In this second study, all important clinical
More news about: SOLIGENIX, INC.
Nov 19, 2025, 00:29 ET Max Stock Limited Reports Third Quarter 2025 Financial Results
primarily attributable to trade and supply chain efficiency gains enabled by the Company's new logistics center, combined with the strengthening of the ILS vs. the USD and lower shipping costs. Selling, general and administrative expenses were ILS 107.0 million in the third quarter 2025
More news about: Max Stock Limited
Nov 18, 2025, 19:30 ET LUCA MINING CORP. REPORTS THIRD QUARTER 2025 RESULTS
engagement across both sites. Throughput increased: consolidated tonnes milled of 250,807 (+66% vs. prior year), supported by increased plant availability at both mines which has resulted in higher metal output:Gold increased
More news about: Luca Mining Corp.
Nov 18, 2025, 19:06 ET New data on lecanemab to be presented at CTAD conference
Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States (P361)
More news about: BioArctic
Nov 18, 2025, 19:02 ET New data on lecanemab to be presented at CTAD conference
Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States (P361)
More news about: BioArctic
Nov 18, 2025, 11:03 ET Inspire Medical Systems, Inc. (INSP) Faces Investor Suit Over Disastrous Inspire V Launch-- Hagens Berman
and onboarding criteria required prior to the purchase and implant of Inspire V." The company also said that, although Inspire V's CPT code was approved for Medicare patients, "software updates for claims submissions and processing did not take effect until July 1." This meant that
More news about: Hagens Berman Sobol Shapiro LLP
Nov 18, 2025, 10:30 ET ASUS Unveils Comprehensive Storage Solutions at SC25
VS320D-RS12Featuring active-active controller design with Intel® Xeon® processors, these systems provide enterprise-grade
More news about: ASUS Computer International
Nov 18, 2025, 09:00 ET Contextual Intelligence Becomes the New Standard for Exceptional Customer Experience in 2026
improving data and analytics. High-maturity firms track AI-driven metrics at triple the rate of low-maturity peers, including automation success rates (66% vs 21%). AI transparency has become a non-negotiable expectation, with consumers demanding clear
More news about: Zendesk, Inc.
Nov 18, 2025, 08:56 ET New Cornerstone Advisors Research Finds Community Banks and Credit Unions Only Halfway to Successfully Leveraging Their Data
analytics capabilities. Credit unions outperformed banks significantly in every functional area, scoring an average of 271 vs. 211, suggesting stronger data-driven cultures within the credit union sector. Larger financial institutions generally achieved
More news about: Cornerstone Advisors
Nov 18, 2025, 08:49 ET Crypto's Great Deception: 75% of "Decentralized" Currency Controlled by Centralized Giants
degen casino model" of speculative chaos. In this scenario, participants repeatedly mint and trade meme tokens as though playing a peer-vs-peer casino — chasing short-term wins where most tokens collapse to near-zero value. (6)
More news about: Dr. David Utzke
Nov 18, 2025, 08:36 ET Colling Media Wins Top Honors at 2025 Netty Awards for Knight Transportation Campaign
thinking to ensure the new domain wasn't just functional, but future-focused. Key results following launch (September 2024–June 2025 vs. prior period) included: +49.5% sessions +44.5% new users
More news about: Colling Media
Nov 18, 2025, 08:00 ET Vasa Therapeutics Granted FDA Fast Track Designation for VS-041, a Novel Investigational Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
advance VS-041 through clinical development." VS-041 is an oral small molecule inhibitor of MMP-2 and -9 with a demonstrated ability to ameliorate the underlying fibroinflammation in preclinical models of HFpEF. In a Phase 1 clinical trial completed earlier this year, VS-041 was
More news about: Vasa Therapeutics
Nov 18, 2025, 08:00 ET Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States (P361)
More news about: Eisai Inc.
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent
More news about: Acurx Pharmaceuticals, Inc.
Nov 18, 2025, 07:51 ET Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
Superior Prediction vs. KFRE kidneyintelX.dkd outperformed the Kidney Failure Risk Equation (KFRE) in predicting kidney
More news about: Renalytix plc
Nov 18, 2025, 07:45 ET Kikoff Integrates Optimal Path™ Interactive Score Planner from Equifax
said Cynthia Chen, Founder and CEO of Kikoff. "Optimal Path offers deeply personalized plans that encourage more engagement and financial improvement vs. generic credit-building tools. No matter what a member's current financial situation is, Optimal Path is a true differentiator that can help our members
More news about: Equifax Inc.